QURE Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -28.23%, SMA50 -27.34%, SMA200 -31.94%). The stock’s 14-day RSI is 34.7 (weak momentum), while the ATR of 2.56 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -76.06% below its high and over 120.55% above its low. Average 10-day trading volume of 1.96 million shares is below the 3-month average of 3.06 million, indicating normal recent market interest.

uniQure N.V. has 54.87 million shares outstanding. The public float is 38.74 million shares, elevated short interest at 16.73% of float. This equals 9.06 million shares. The short ratio is 8.42 days. Institutional investors hold 108.1% of the float. Insiders own 5.61%. Kapusta Matthew C holds 660.66 thousand shares, KLEMT CHRISTIAN has 226.58 thousand shares and Abi-Saab Walid has 189.67 thousand shares. Over the past six months, insider transactions show net selling. They sold 154.20 thousand shares across 14 transactions.

uniQure N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$8.56. This means the shares are trading below this model’s fair value.

uniQure N.V. (NASDAQ:QURE) closed at $20.68 USD, gaining $1.55 (8.10%) from the previous close of $19.13. The stock is currently mid-range between its 52-week high and low $8.73 and $71.50. With a market capitalization of about $1.27 billion, uniQure N.V. is classified as a small-cap and shows market-like volatility (beta ~0.87). Key stats such as the average daily volume over the past year has been around 3.18 million shares, volume is running light vs its 52-week average. Headquartered in Amsterdam, None, uniQure N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Matthew Craig Kapusta, the company employs approximately 209 people and listed since February 05, 2014. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.

uniQure N.V. generated EPS of -$4.39 over the past year. Five-year average earnings growth is -9.66%. Wall Street analysts project EPS growth of 29.0% annually over the next five years. The latest quarter delivered EPS of -$0.56. The next quarter is forecast at -$0.92. Next year's EPS is expected at $36.22. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 20 Buy ratings, 9 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $110.00 to $10.00. The high target offers 431.91% upside. The low target suggests -51.64% downside. The mean target is $54.98. This offers 165.86% upside. uniQure N.V. earnings surprise history is a mixed track record. The quarter that ended March 02, 2026, missed forecasts by -39.78%. The prior quarter beat by 61.9%. Over the last six quarters, Apple has recorded several small beats. These include -9.9% in November 05, 2024.

uniQure N.V. trades at a P/E ratio of -5.95, slightly below the S&P 500 average, with a price-to-sales ratio of 78.77 and a price-to-book ratio of 5.95 trading at moderately above to book value. The P/FCF stands at -7.13, also below market averages.

uniQure N.V. (NASDAQ:QURE) shares are flat -6.39% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows uniQure N.V. trading at a premium to the broader market with a P/E of -5.95. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $49.99, suggesting 141.73% upside. Our AI forecast model points to short-term strength (3.77% over two weeks), a medium-term fall (-61.8% over three months), and a longer-term gain (26.16% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that uniQure N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.77%, with price expected at $21.46 by May 18, 2026, within a range of $20.30 to $22.51 3-Month Outlook: Projected fall of -61.8%, reaching $7.90 by July 31, 2026, with a range of $2.79 to $8.43. 1-Year Outlook: Projected gain of 26.16%, with price at $26.09 by May 04, 2027, within a range of $22.20 to $29.68.